INFINITY PHARMA

Active

Public limited companyfounded 197649 yrs activeVenecoweg 20A, 9810 Nazareth-De Pinte, BelgiumKBO/BCE: BE 0416.616.681

Summary

INFINITY PHARMA has been active since 1976 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €16.4m and a net result of -€231,419. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 91% of 5046 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).

Risk analysis Watch Report Compare

INFINITY PHARMAActiveChecked score 72/100

Risk analysis Report Compare

Checked score

Score 2025

72 / 100

Healthy

Every signal that weighs is under Signals.

Axes · tick = 2024

Profitability20▲+10

Solvency100=

Growth46▲+1

Track record100

Bankruptcy probability, 12 months

0.2% Very low

0%0.5%1.5%4%10%≥ 25%

Credit up to €1,050,000 at 30 days acceptable

Liquidity tight (current ratio 1.44 against 1.06 in 2024; short-term debt: 12.8% and cash: 3.7% of total assets), and 12.8% of the assets are financed with debt.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Five signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Annual accounts: healthy financial profile

The latest annual accounts show a healthy profile in solvency, result and liquidity.

NBB · annual accounts 2025

Solvency, return and age of the figures

Solvency

87.2%

Return on assets

-1.2%

Age of the figures

9 mo

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Higher-failure-rate sector

In this sector companies fail more often than the Belgian average.

Gazette · bankruptcies per sector, NACE 46

Relative position

BE, all sectors

reference

Wholesale trade (NACE 46)

about 21% more bankruptcies

← fewer bankruptcies more bankruptcies →

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 11-06-2026, 50 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

50 d early

2024

46 d late

2023

54 d early

2022

56 d early

2021

61 d early

2020

67 d early

2019

61 d early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 43 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

28-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

History

INFINITY PHARMA was incorporated on 8 December 1976.¹ Between 2005 and 2023 the company absorbed 8 companies by merger, including INFINITY PHARMA and PHARMA-PACK.²³⁴ The name was changed to ACA PHARMA in 2009 and to Infinity Pharma in 2026.⁵⁶ The registered office moved to Waregem in 2009 and to Nazareth in 2016.⁵⁷ Between 2014 and 2026 the capital was increased 4 times, most recently to EUR 13 million.⁸⁹¹⁰ The board currently has 4 members; Céline Caveye has served longest, since 2016.¹¹ Revenue went from EUR 11 million in 2023 to EUR 11 million in 2025 and headcount from 19.1 to 13.6 full-time equivalents.¹²

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed

Is this your company? See how customers and banks see it.

Investigating this company? Keep it with today's facts in a case file.

Financials · fiscal year 2025, full schema

In the rankings #7 company by equity in Nazareth-De Pinte, Wholesale and retail trade sector #8 company by total assets in Nazareth-De Pinte, Wholesale and retail trade sector

Turnover

€10.7m▲ 0.6%

2024 · €10.7m

EBIT margin

-0.7%▲ 4.3pp

2024 · -5.0%

Net result

-€231,419▲ 71.9%

2024 · -€822,517

Working capital

€1.1m▲ 425%

2024 · €200,859

Trend over the years

Chart Table

Click a name to add, emphasise or remove a line.Band: the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings. Dashed line: the median.

Every figure with its change against the fiscal year before

favourable unfavourable

Line20212022202320242025

Turnover€10.2m▼ 34.7%€7.2m▼ 29.8%€11.4m▲ 58.3%€10.7m▼ 6.2%€10.7m▲ 0.6%

Operating result-€450,494-€54,232▲ 88.0%-€285,893▼ 427%-€531,006▼ 85.7%-€72,613▲ 86.3%

Net result-€6.4m-€503,430▲ 92.2%-€7.4m▼ 1,364%-€822,517▲ 88.8%-€231,419▲ 71.9%

EBIT margin-4.4%▼ 18.4pp-0.8%▲ 3.6pp-2.5%▼ 1.8pp-5.0%▼ 2.5pp-0.7%▲ 4.3pp

Equity€31.3m▼ 17.0%€5.8m▼ 81.4%-€1.6m€12.6m€16.4m▲ 29.8%

Total assets€82.0m▼ 8.9%€53.1m▼ 35.3%€47.2m▼ 11.1%€16.0m▼ 66.2%€18.8m▲ 17.8%

Debt€50.7m▼ 3.1%€47.3m▼ 6.8%€48.8m▲ 3.2%€3.3m▼ 93.2%€2.4m▼ 27.8%

Working capital€25.8m▲ 2.3%-€7.2m-€14.1m▼ 97.2%€200,859€1.1m▲ 425%

Solvency38.2%▼ 3.7pp11.0%▼ 27.2pp-3.3%▼ 14.2pp79.1%▲ 82.4pp87.2%▲ 8.1pp

Current ratio1.51▲ 0.030.85▼ 0.660.71▼ 0.141.06▲ 0.351.44▲ 0.38

Return on assets (ROA)-7.8%▼ 39.3pp-0.9%▲ 6.9pp-15.6%▼ 14.7pp-5.2%▲ 10.5pp-1.2%▲ 3.9pp

Staff (FTE)9.8▲ 2.1%9.8=19.1▲ 94.9%19.8▲ 3.7%13.6▼ 31.3%

above within below the middle half (P25 to P75) of NACE 46, Wholesale trade, each year against the same schema; no band under 30 filings.

Why a figure moved sharply

2024 Net result +89% on 2023. Merger absorbing PHARMA-PACK, effective 21-06-2023, in the previous fiscal year; now counts for a full year for the first time.
2023 Turnover +58%, Net result -1,364%, Staff (FTE) +95% on 2022. Merger absorbing PHARMA-PACK, effective 21-06-2023.
2022 Net result +92% on 2021. Merger absorbing INFINITY PHARMA, Official Gazette 26-07-2021, in the previous fiscal year; now counts for a full year for the first time.

Result per fiscal year

Operating resultNet result

The operating result stays negative: a loss of €72,613 in 2025 against €531,006 in 2024; the loss shrinks.

Balance-sheet composition

2025 in colour, 2024 as the grey bar beneath

Assets €18.8m

81.6%

18.4%

Fixed assets €15.3m ▲ 23.4%

Current assets €3.5m ▼ 2.1%

Equity and liabilities €18.8m

87.2%

12.8%

Equity €16.4m ▲ 29.8%

Debt €2.4m ▼ 27.8%

Debt's share of the balance-sheet total falls from 20.9% to 12.8%. Equity is higher and debt is lower.

Key figures and ratios

2025 value · change against 2024

EBITDA

€19,095▲

2024 · -€413,899

Cash flow

-€139,711▲

2024 · -€705,411

Quick ratio

0.41▲

2024 · 0.27

Debt to equity

0.15▼

2024 · 0.26

ROE

-1.4%▲

2024 · -6.5%

Interest coverage

0.35▲

2024 · -0.25

Debt ≤ 1 year

€2.4m▼

2024 · €3.3m

Income taxes

€3,500▲

2024 · -€1,081

Staff costs

€1.5m▼

2024 · €2.0m

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Annual accounts

OverviewIncome statement Balance sheet Cash flow

Filed annual accounts As filed with the NBB · 2025 against 2024 · 85 lines

Balance sheet Code20242025

Assets

Total assets20/58€16.0m€18.8m▲

Fixed assets21/28€12.4m€15.3m▲

Intangible fixed assets21€380,797€295,564▼

Tangible fixed assets22/27€43,234€42,730▼

Plant, machinery and equipment23€17,151€18,529▲

Furniture and vehicles24€5,018€5,717▲

Assets under construction and advance payments27€21,065€18,484▼

Financial fixed assets28€12.0m€15.0m▲

Affiliated companies280/1€12.0m€15.0m▲

Participating interests280€12.0m€15.0m▲

Other financial fixed assets284/8€2,618€2,618=

Amounts receivable and cash guarantees285/8€2,618€2,618=

Current assets29/58€3.5m€3.5m▼

Stocks and contracts in progress3€2.6m€2.5m▼

Stocks30/36€2.6m€2.5m▼

Raw materials and consumables30/31€821,801€809,905▼

Work in progress32€0-

Finished goods33€256,016€519,505▲

Goods purchased for resale34€1.6m€1.2m▼

Amounts receivable within one year40/41€729,162€254,222▼

Trade receivables40€569,705€253,448▼

Other amounts receivable41€159,457€773▼

Current investments50/53€0€0=

Own shares50€0€0=

Cash at bank and in hand54/58€164,043€688,336▲

Deferred charges and accrued income490/1€14,686€35,067▲

Equity and liabilities

Total equity and liabilities10/49€16.0m€18.8m▲

Equity10/15€12.6m€16.4m▲

Contributions10/11€9.3m€13.3m▲

Capital10€9.3m€13.3m▲

Issued capital100€9.3m€13.3m▲

Reserves13€4.2m€3.3m▼

Non-distributable reserves130/1€1.3m€1.3m=

Legal reserve130€1.3m€1.3m=

Own shares acquired1312€0€0=

Tax-exempt reserves132€18,924€18,924=

Distributable reserves133€2.8m€2.0m▼

Profit (loss) carried forward14-€822,517-€231,419▲

Amounts payable17/49€3.3m€2.4m▼

Amounts payable within one year42/48€3.3m€2.4m▼

Financial debts43€0€0=

Other loans439€0€0=

Trade debts44€2.4m€2.2m▼

Suppliers440/4€2.4m€2.2m▼

Advances received on contracts in progress46€4,972€4,972=

Taxes, remuneration and social security45€321,840€182,799▼

Taxes450/3€152,444€32,691▼

Remuneration and social security454/9€169,396€150,108▼

Other amounts payable47/48€654,808€104▼

Income statement Code20242025

Operating income70/76A€11.0m€11.3m▲

Turnover70€10.7m€10.7m▲

Change in stocks of work in progress, finished goods and contracts in progress71-€263,489

Own construction capitalised72€0€18,484▲

Other operating income74€344,394€272,894▼

Operating charges60/66A€11.6m€11.4m▼

Goods for resale, raw materials and consumables60€6.1m€6.3m▲

Purchases600/8€6.0m€5.8m▼

Change in stocks: decrease (increase)609€150,173€523,187▲

Services and other goods61€3.0m€3.5m▲

Remuneration, social security and pensions62€2.0m€1.5m▼

Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€117,106€91,708▼

Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4€111,112-€116,202▼

Other operating charges640/8€16,994€97,521▲

Non-recurring operating charges66A€182,177-

Operating profit (loss)9901-€531,006-€72,613▲

Financial income75/76B€1.5m€167,254▼

Recurring financial income75€1.5m€167,238▼

Income from current assets751€1.5m€773▼

Other financial income752/9€6,072€166,464▲

Non-recurring financial income76B€327€17▼

Financial charges65/66B€1.8m€322,561▼

Recurring financial charges65€1.8m€322,561▼

Debt charges650€1.7m€53,813▼

Other financial charges652/9€106,954€268,748▲

Profit (loss) for the period before taxes9903-€823,599-€227,919▲

Income taxes67/77-€1,081€3,500▲

Taxes670/3-€3,500

Tax adjustments and reversals of tax provisions77€1,081-

Profit (loss) for the period9904-€822,517-€231,419▲

Profit (loss) for the period to be appropriated9905-€822,517-€231,419▲

Appropriation of the result

Profit (loss) to be appropriated9906-€822,517-€1.1m▼

Profit (loss) brought forward from the previous period14P--€822,517

Transfer from equity791/2-€822,517

From reserves792-€822,517

Social balance

Average headcount (FTE)908719.813.6▼

The notes to these accounts (73 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line	2021	2022	2023	2024	2025	Change
Operating income70/76A	€10.4m	€7.3m	€11.9m	€11.0m	€11.3m	▲ 2.5%
Turnover70	€10.2m	€7.2m	€11.4m	€10.7m	€10.7m	▲ 0.6%
Change in stocks of work in progress, finished goods and contracts in progress71	-	-	-	-	€263,489	-
Own construction capitalised72	-	-	€327,457	€0	€18,484	-
Other operating income74	€176,689	€93,347	€157,635	€344,394	€272,894	▼ 20.8%
Non-recurring operating income76A	€3,600	-	-	-	-	-
Operating charges60/66A	€10.9m	€7.3m	€12.2m	€11.6m	€11.4m	▼ 1.6%
Goods for resale, raw materials and consumables60	€7.0m	€4.3m	€6.2m	€6.1m	€6.3m	▲ 3.9%
Purchases600/8	€6.1m	€4.5m	€7.7m	€6.0m	€5.8m	▼ 2.3%
Change in stocks: decrease (increase)609	€930,324	-€239,054	-€1.5m	€150,173	€523,187	▲ 248%
Services and other goods61	€2.5m	€2.1m	€3.4m	€3.0m	€3.5m	▲ 16.3%
Remuneration, social security and pensions62	€1.4m	€920,474	€2.4m	€2.0m	€1.5m	▼ 27.5%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630	€37,656	€15,731	€60,357	€117,106	€91,708	▼ 21.7%
Write-downs on stocks, contracts in progress and trade receivables: additions (reversals)631/4	-€75,416	-€32,887	€124,384	€111,112	-€116,202	▼ 205%
Provisions for liabilities and charges: additions (uses and reversals)635/8	-€3,603	-	-	-	-	-
Other operating charges640/8	€8,820	€113,663	€28,840	€16,994	€97,521	▲ 474%
Non-recurring operating charges66A	-	-	-	€182,177	-	-
Operating profit (loss)9901	-€450,494	-€54,232	-€285,893	-€531,006	-€72,613	▲ 86.3%
Financial income75/76B	€731,803	€894,149	€1.5m	€1.5m	€167,254	▼ 88.7%
Recurring financial income75	€731,803	€893,650	€1.5m	€1.5m	€167,238	▼ 88.7%
Income from current assets751	€728,140	€890,146	€1.5m	€1.5m	€773	▼ 99.9%
Other financial income752/9	€3,663	€3,504	€8,040	€6,072	€166,464	▲ 2,642%
Non-recurring financial income76B	-	€499	-	€327	€17	▼ 94.9%
Financial charges65/66B	€6.7m	€1.5m	€8.6m	€1.8m	€322,561	▼ 81.9%
Recurring financial charges65	€1.2m	€1.5m	€2.9m	€1.8m	€322,561	▼ 81.9%
Debt charges650	€1.1m	€1.4m	€2.7m	€1.7m	€53,813	▼ 96.8%
Other financial charges652/9	€134,566	€106,502	€134,554	€106,954	€268,748	▲ 151%
Non-recurring financial charges66B	€5.5m	-	€5.7m	-	-	-
Profit (loss) for the period before taxes9903	-€6.4m	-€664,933	-€7.4m	-€823,599	-€227,919	▲ 72.3%
Income taxes67/77	-€6,102	-€161,504	€4,042	-€1,081	€3,500	▲ 424%
Taxes670/3	-	€1,712	€4,042	-	€3,500	-
Tax adjustments and reversals of tax provisions77	€6,102	€163,215	-	€1,081	-	-
Profit (loss) for the period9904	-€6.4m	-€503,430	-€7.4m	-€822,517	-€231,419	▲ 71.9%
Profit (loss) for the period to be appropriated9905	-€6.4m	-€503,430	-€7.4m	-€822,517	-€231,419	▲ 71.9%

Line	2021	2022	2023	2024	2025	Change
Assets
Total assets20/58	€82.0m	€53.1m	€47.2m	€16.0m	€18.8m	▲ 17.8%
Fixed assets21/28	€5.6m	€13.0m	€12.5m	€12.4m	€15.3m	▲ 23.4%
Intangible fixed assets21	€6,641	€2,244	€287,821	€380,797	€295,564	▼ 22.4%
Tangible fixed assets22/27	€40,034	€33,075	€251,398	€43,234	€42,730	▼ 1.2%
Plant, machinery and equipment23	€39,616	€28,586	€28,972	€17,151	€18,529	▲ 8.0%
Furniture and vehicles24	€418	€115	€8,064	€5,018	€5,717	▲ 13.9%
Leasing and similar rights25	-	-	€0	-	-	-
Other tangible fixed assets26	-	-	€0	-	-	-
Assets under construction and advance payments27	-	€4,375	€214,362	€21,065	€18,484	▼ 12.3%
Financial fixed assets28	€5.5m	€12.9m	€12.0m	€12.0m	€15.0m	▲ 25.0%
Affiliated companies280/1	€5.5m	€12.9m	€12.0m	€12.0m	€15.0m	▲ 25.0%
Participating interests280	€5.5m	€12.9m	€12.0m	€12.0m	€15.0m	▲ 25.0%
Other financial fixed assets284/8	€614	€614	€2,618	€2,618	€2,618	=
Amounts receivable and cash guarantees285/8	€614	€614	€2,618	€2,618	€2,618	=
Current assets29/58	€76.5m	€40.1m	€34.7m	€3.5m	€3.5m	▼ 2.1%
Stocks and contracts in progress3	€1.2m	€1.5m	€2.9m	€2.6m	€2.5m	▼ 5.5%
Stocks30/36	€1.2m	€1.5m	€2.9m	€2.6m	€2.5m	▼ 5.5%
Raw materials and consumables30/31	-	€203,666	€957,713	€821,801	€809,905	▼ 1.4%
Work in progress32	-	€11,724	€64	€0	-	-
Finished goods33	-	€31,691	€216,172	€256,016	€519,505	▲ 103%
Goods purchased for resale34	€1.2m	€1.2m	€1.7m	€1.6m	€1.2m	▼ 25.4%
Amounts receivable within one year40/41	€75.0m	€38.5m	€31.5m	€729,162	€254,222	▼ 65.1%
Trade receivables40	-	€255,666	€414,182	€569,705	€253,448	▼ 55.5%
Other amounts receivable41	€75.0m	€38.2m	€31.1m	€159,457	€773	▼ 99.5%
Current investments50/53	€0	€0	€0	€0	€0	=
Own shares50	€0	€0	€0	€0	€0	=
Cash at bank and in hand54/58	€249,096	€147,193	€276,447	€164,043	€688,336	▲ 320%
Deferred charges and accrued income490/1	€17,272	€9,166	€28,069	€14,686	€35,067	▲ 139%
Equity and liabilities
Total equity and liabilities10/49	€82.0m	€53.1m	€47.2m	€16.0m	€18.8m	▲ 17.8%
Equity10/15	€31.3m	€5.8m	-€1.6m	€12.6m	€16.4m	▲ 29.8%
Contributions10/11	€1.7m	€1.7m	€1.7m	€9.3m	€13.3m	▲ 43.0%
Capital10	€1.7m	€1.7m	€1.7m	€9.3m	€13.3m	▲ 43.0%
Issued capital100	€1.7m	€1.7m	€1.7m	€9.3m	€13.3m	▲ 43.0%
Reserves13	€29.7m	€4.2m	€4.2m	€4.2m	€3.3m	▼ 19.8%
Non-distributable reserves130/1	€1.3m	€1.3m	€1.3m	€1.3m	€1.3m	=
Legal reserve130	€1.3m	€1.3m	€1.3m	€1.3m	€1.3m	=
Own shares acquired1312	€0	€0	€0	€0	€0	=
Tax-exempt reserves132	€18,924	€18,924	€18,924	€18,924	€18,924	=
Distributable reserves133	€28.4m	€2.8m	€2.8m	€2.8m	€2.0m	▼ 28.9%
Profit (loss) carried forward14	-	-	-€7.4m	-€822,517	-€231,419	▲ 71.9%
Amounts payable17/49	€50.7m	€47.3m	€48.8m	€3.3m	€2.4m	▼ 27.8%
Amounts payable within one year42/48	€50.7m	€47.3m	€48.8m	€3.3m	€2.4m	▼ 27.8%
Current portion of amounts payable after more than one year42	-	-	€0	-	-	-
Financial debts43	€48.5m	€44.9m	€44.9m	€0	€0	-
Other loans439	€48.5m	€44.9m	€44.9m	€0	€0	-
Trade debts44	€1.7m	€2.0m	€2.5m	€2.4m	€2.2m	▼ 5.7%
Suppliers440/4	€1.7m	€2.0m	€2.5m	€2.4m	€2.2m	▼ 5.7%
Advances received on contracts in progress46	€4,972	€4,972	€4,972	€4,972	€4,972	=
Taxes, remuneration and social security45	€493,416	€330,422	€658,317	€321,840	€182,799	▼ 43.2%
Taxes450/3	€328,845	€144,192	€228,691	€152,444	€32,691	▼ 78.6%
Remuneration and social security454/9	€164,571	€186,230	€429,627	€169,396	€150,108	▼ 11.4%
Other amounts payable47/48	€3,891	-	€714,704	€654,808	€104	▼ 100.0%
Accrued charges and deferred income492/3	€815	-	-	-	-	-

Line	2021	2022	2023	2024	2025	Change
Profit (loss) for the period9904	-€6.4m	-€503,430	-€7.4m	-€822,517	-€231,419	▲ 71.9%
+ Depreciation and write-downs630	€37,656	€15,731	€60,357	€117,106	€91,708	▼ 21.7%
Operating cash flow (approximation)	-€6.4m	-€487,698	-€7.3m	-€705,411	-€139,711	▲ 80.2%
Investment in fixed assets (approximation)	-	-€7.4m	€357,706	-€1,919	-€3.0m	▼ 156,581%
Change in cash	-	-€101,902	€129,253	-€112,403	€524,292	▲ 566%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Timeline · acts, filings and financial milestones

All 70Financial 6Gazette 54Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

07-07

State Gazette act Resignation: VERLINDEN Johan (director)

Name change · Power of attorney5 facts ▸

General meeting, 29-06-2026
Name change, Infinity Pharma
Director resignation, VERLINDEN Johan (director)
Power of attorney
Power of attorney, Stijn RAES

11-06

NBB filing Annual accounts filed

fiscal year 2025 · full schema

02-01

State Gazette act Capital & shares

Capital increase · Bank account · Capital6 facts ▸

General meeting, 16-12-2025
Capital increase, €4.000.000
Bank account, 15-12-2025
Capital, €13.300.000
Power of attorney, Stijn RAES
Power of attorney, het bestuursorgaan

2025

31-12

State Gazette act Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)

Permanent representative: Lien Winne · Mandate compensation4 facts ▸

General meeting, 06/10/2025
Auditor appointment, PwC Bedrijfsrevisoren BV (statutory auditor)
Permanent representative, Lien Winne (permanent representative)
Mandate compensation, PwC Bedrijfsrevisoren BV

15-09

NBB filing Annual accounts filed

fiscal year 2024 · full schema · 46 days late

23-01

State Gazette act Capital & shares

Capital increase · Bank account · Capital decrease6 facts ▸

General meeting, 20/12/2024
Capital increase, €15.009.359,36
Bank account, 20/12/2024
Capital decrease, €7.368.329,98
Capital, €9.300.000
Power of attorney, Franck Cléty

2024

31-12

Financial Equity above €10mEq €12.6m

Equity rises from -€1.6m to €12.6m.

26-08

State Gazette act Reappointment: Padilla Rafael (director)

2 facts ▸

General meeting, 09/05/2023
Director reappointment, Padilla Rafael (director)

07-06

NBB filing Annual accounts filed

fiscal year 2023 · full schema

2023

31-12

Financial Weakest financial yearnet -€7.4m

Net result drops to -€7.4m, the lowest in the series; recovery starts the following year.

03-08

State Gazette act Restructuring

Merger · Name change · Power of attorney5 facts ▸

General meeting, 21/06/2023
Merger, 21/06/2023
Name change, PHARMA-PACK
Power of attorney, CLETY Franck
Power of attorney, William VAN LANCKER

05-06

NBB filing Annual accounts filed

fiscal year 2022 · full schema

Show earlier events

03-05

State Gazette act Restructuring

Merger · Power of attorney · Accounting effect5 facts ▸

Board meeting, 01/04/2023
Merger
Power of attorney, William Van Lancker
Power of attorney, Franck Cléty
Accounting effect, 01/01/2023

2022

22-12

State Gazette act Appointments: Johan Verlinden (director) and Céline Caveye (director)

Power of attorney4 facts ▸

General meeting, 11/05/2021
Director appointment, Johan Verlinden (director)
Director appointment, Céline Caveye (director)
Power of attorney, William Van Lancker

22-12

State Gazette act Reappointment: De Jong Cormelia Neeltje (director)

Appointment: Deloitte Bedrijfsrevisoren CVBA (statutory auditor) · Approval · Director discharge7 facts ▸

General meeting, 10/05/2022
Approval, jaarrekening afgesloten op 31 december 2021
Director reappointment, De Jong Cormelia Neeltje (director)
Auditor appointment, Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
Director discharge, INFINITY PHARMA
Director discharge, INFINITY PHARMA
Financial result, -6421844.19, EUR

31-05

NBB filing Annual accounts filed

fiscal year 2021 · full schema

2021

26-07

State Gazette act Capital & shares · Purpose · Statutes amendment · Restructuring

Merger · Name change · Capital7 facts ▸

Merger, met fusie door overneming gelijkgestelde verrichting
Name change, INFINITY PHARMA
Statutes amendment
Statutes amendment
Capital, €1.658.970,62
Power of attorney, DELAMEILLEURE Tim
Power of attorney, CLETY Franck

25-05

NBB filing Annual accounts filed

fiscal year 2020 · full schema

21-05

State Gazette act Resignations: Hernando Acosta (day-to-day manager) and Bart Ameije (day-to-day manager)

Appointment: Peter De Sutter (day-to-day manager) · Director discharge5 facts ▸

Director resignation, Hernando Acosta (day-to-day manager)
Director resignation, Bart Ameije (day-to-day manager)
Director discharge, Hernando Acosta
Director discharge, Bart Ameije
Director appointment, Peter De Sutter (day-to-day manager)

27-04

State Gazette act Restructuring · Miscellaneous

Power of attorney · Merger · Accounting effect5 facts ▸

Board meeting, 01/04/2021
Power of attorney, Tim Delameilleure
Power of attorney, Franck Cléty
Merger
Accounting effect, 01/01/2021

2020

31-12

Financial Highest result since 2018net €28.4m ▲113%

Operating result €2.2m, net result €28.4m, both a record.

31-12

Financial Liquidity times 6current ratio 1.48

Current ratio from 0.26 to 1.48; short-term debt falls from €56.6m to €52.3m.

31-12

Financial Equity above €25mEq €37.7m ▲303%

3 profitable years in a row build equity to €37.7m.

19-11

State Gazette act Appointment: Hernando Acosta (day-to-day manager)

2 facts ▸

Board meeting, 01/10/2020
Director appointment, Hernando Acosta (day-to-day manager)

13-08

State Gazette act Capital & shares · Restructuring

Merger · Net-asset statement2 facts ▸

Merger
Net-asset statement, 31/12/2019

10-06

State Gazette act Restructuring

Merger · Power of attorney · Accounting effect5 facts ▸

Board meeting, 28 mei 2020
Merger
Power of attorney, Tim Delameilleure
Power of attorney, Franck Cléty
Accounting effect, 1 januari 2020

31-05

NBB filing Annual accounts filed

fiscal year 2019 · full schema

2019

31-12

Financial Equity above €5mEq €9.4m ▲209%

2 profitable years in a row build equity to €9.4m.

26-11

State Gazette act Appointment: Bart Ameije (day-to-day manager)

2 facts ▸

Board meeting, 01/09/2019
Director appointment, Bart Ameije (day-to-day manager)

16-10

State Gazette act Appointment: Deloitte Bedrijfsrevisoren CVBA (statutory auditor)

Permanent representative: Ine Nuyts3 facts ▸

General meeting, 24/06/2019
Auditor appointment, Deloitte Bedrijfsrevisoren CVBA (statutory auditor)
Permanent representative, Ine Nuyts

05-06

State Gazette act Resignation: Jumoo bvba (day-to-day manager)

Director discharge3 facts ▸

Board meeting, 25/03/2019
Director resignation, Jumoo bvba (day-to-day manager)
Director discharge, Jumoo bvba

23-05

NBB filing Annual accounts filed

fiscal year 2018 · full schema

2018

27-12

State Gazette act Resignations & appointments · Restructuring

Merger · Net-asset statement · Power of attorney5 facts ▸

Merger
Merger
Net-asset statement, 31/08/2018
Power of attorney, Tim DELAMEILLEURE
Power of attorney, Katja VAN DALSEN

17-10

State Gazette act Restructuring

Power of attorney · Merger · Accounting effect5 facts ▸

Board meeting, 06/09/2018
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Merger
Accounting effect, 01/09/2018

17-10

State Gazette act Restructuring

Merger · Power of attorney · Accounting effect4 facts ▸

Merger
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Accounting effect, 01/09/2018

10-07

State Gazette act Capital & shares · Statutes amendment

Merger · Capital increase · Power of attorney7 facts ▸

General meeting, 11/06/2018
Merger, absorption, 31/12/2017
Capital increase, €99.873,22
Capital increase, €859.098,16
Statutes amendment
Power of attorney, Tim DELAMEILLEURE
Power of attorney, Katja VAN DALSEN

23-05

NBB filing Annual accounts filed

fiscal year 2017 · full schema

24-04

State Gazette act Restructuring

Appointment: PwC Bedrijfsrevisoren BCVBA (statutory auditor) · Merger · Power of attorney15 facts ▸

Board meeting, 19/03/2018
Merger
Power of attorney, Tim Delameilleure
Power of attorney, Katja van Dalsen
Net-asset statement, 31/12/2017
Net-asset statement, 31/12/2017
Share issue, 170.635
Accounting effect, 01/01/2018
Auditor appointment, PwC Bedrijfsrevisoren BCVBA
Auditor fee, 7.000, EUR
Dissolution, zonder vereffening
Exchange ratio, per share, 5,62
+3 further facts in this act

08-02

State Gazette act Resignation: Johannes Stols (director)

Appointments: Rafael Padilla (director) and Cornelia de Jong (managing director) · Director discharge · Mandate compensation7 facts ▸

General meeting, 04/12/2017
Board meeting, 04/12/2017
Director resignation, Johannes Stols (director)
Director discharge, Johannes Stols
Director appointment, Rafael Padilla (director)
Mandate compensation, Rafael Padilla
Director appointment, Cornelia de Jong (managing director)

2017

04-12

State Gazette act Capital & shares · Miscellaneous

General meeting1 fact ▸

General meeting, 25/10/2017

30-11

State Gazette act Capital & shares

Capital decrease · Statutes amendment · Power of attorney4 facts ▸

General meeting, 31/10/2017
Capital decrease, €186.169.363,76
Statutes amendment
Power of attorney, Johan VERLINDEN

04-10

State Gazette act Resignation: Kalman Petro (day-to-day manager)

Appointment: Jumoo bvba (day-to-day manager) · Permanent representative: Daan Vermeulen · Mandate compensation6 facts ▸

General meeting, 28/08/2017
Director resignation, Kalman Petro (day-to-day manager)
Director appointment, Jumoo bvba (day-to-day manager)
Permanent representative, Daan Vermeulen
Mandate compensation, Jumoo bvba
Mandate limit, 100.000 EUR

26-07

State Gazette act Resignation: Davy de Vlieger (day-to-day manager)

2 facts ▸

Board meeting, 01/06/2017
Director resignation, Davy de Vlieger (day-to-day manager)

31-05

State Gazette act Resignations: Procuram bvba, Christophe Bouvry and Tim Delameilleure

Appointments: Kalman Petro (day-to-day manager) and Davy de Vlieger (day-to-day manager) · Mandate compensation · Financial authorization11 facts ▸

Board meeting, 31/03/2017
Director resignation, Procuram bvba (day-to-day manager)
Director resignation, Christophe Bouvry (day-to-day manager)
Director resignation, Tim Delameilleure (day-to-day manager)
Director appointment, Kalman Petro (day-to-day manager)
Director appointment, Davy de Vlieger (day-to-day manager)
Mandate compensation, Kalman Petro
Mandate compensation, Davy de Vlieger
Financial authorization, 500.000 EUR
Financial authorization, 100.000
Right of substitution, ja

09-05

NBB filing Annual accounts filed

fiscal year 2016 · full schema

26-04

State Gazette act Appointment: BCVBA PwC Bedrijfsrevisoren (statutory auditor)

Permanent representative: Peter Van den Eynde · Mandate term4 facts ▸

General meeting, 30/06/2016
Auditor appointment, BCVBA PwC Bedrijfsrevisoren (statutory auditor)
Permanent representative, Peter Van den Eynde
Mandate term, na de algemene vergadering der aandeelhouders die de jaarekening per 31 december 2018 dient goed te keuren

2016

20-12

State Gazette act Resignations: Jan Peeters nv (director) and Rony Lebotte (day-to-day manager)

Appointments: Cornelia de Jong, Christophe Bouvry and Tim Delameilleure · Director discharge · Mandate compensation9 facts ▸

General meeting, 17/10/2016
Director resignation, Jan Peeters nv (director)
Director discharge, Jan Peeters nv (director)
Director appointment, Cornelia de Jong (director)
Mandate compensation, Cornelia de Jong
Director appointment, Christophe Bouvry (day-to-day manager)
Director appointment, Tim Delameilleure (day-to-day manager)
Director resignation, Rony Lebotte (day-to-day manager)
Financial limit, 1.000.000 EUR

22-11

State Gazette act Appointments: Johan Verlinden (director) and Céline Caveye (director)

3 facts ▸

General meeting, 22/06/2016
Director appointment, Johan Verlinden (director)
Director appointment, Céline Caveye (director)

15-06

State Gazette act Miscellaneous

Change of control2 facts ▸

General meeting, 30/05/2016
Change of control, wijziging van controle

10-05

State Gazette act Permanent representative: Jan Peeters

Registered-office move3 facts ▸

Board meeting, 29/02/2016
Registered-office move, Venecoweg 20A, 9810 Nazareth
Permanent representative, Jan Peeters

23-03

State Gazette act Resignation: Gerardus van Jeveren (director and managing director)

Appointment: Johannes Stols (director)5 facts ▸

General meeting, 12/12/2015
Board meeting, 12/12/2015
Director resignation, Gerardus van Jeveren (director and managing director)
Director appointment, Johannes Stols (director)
Director appointment, Johannes Stols (managing director)

2015

04-02

State Gazette act Miscellaneous

Change of control2 facts ▸

General meeting, 10/12/2014
Change of control, Wijziging van controle

2014

17-07

State Gazette act Resignation: Romani Management BVBA (day-to-day manager)

Permanent representatives: Filip Hoornaert and Michael Hillaert · Appointments: Procuram bvba (day-to-day manager) and Rony Lebotte (day-to-day manager) · Director discharge9 facts ▸

Board meeting, 25/04/2014
Director resignation, Romani Management BVBA (day-to-day manager)
Director discharge, Romani Management BVBA
Permanent representative, Filip Hoornaert
Director appointment, Procuram bvba (day-to-day manager)
Director appointment, Rony Lebotte (day-to-day manager)
Permanent representative, Michael Hillaert
Financial limit, 1.000.000 EUR
Financial limit, 1.000.000 EUR

21-05

State Gazette act Capital & shares

Statutes amendment · Power of attorney3 facts ▸

General meeting, 11/04/2014
Statutes amendment
Power of attorney, Susana González Melón

05-05

State Gazette act Capital & shares · Resignations & appointments

Capital increase · Statutes amendment · Power of attorney4 facts ▸

General meeting, 25 maart 2014
Capital increase, €133.977.156
Statutes amendment
Power of attorney, Rony LEBOTTE

26-02

State Gazette act Appointments: Romani Management BVBA (day-to-day manager) and Rony Lebotte (day-to-day manager)

Permanent representative: Filip Hoornaert · Financial limit6 facts ▸

Board meeting
Director appointment, Romani Management BVBA (day-to-day manager)
Director appointment, Rony Lebotte (day-to-day manager)
Permanent representative, Filip Hoornaert
Financial limit, 1000000 EUR
Financial limit, 1000000 EUR

06-02

State Gazette act Appointment: BCVBA PwC Bedrijfsrevisoren (statutory auditor)

Permanent representative: Peter Van den Eynde · Mandate term4 facts ▸

General meeting, 14/05/2013
Auditor appointment, BCVBA PwC Bedrijfsrevisoren (statutory auditor)
Permanent representative, Peter Van den Eynde
Mandate term, na de algemene vergadering der aandeelhouders die de jaarrekening per 31 december 2015 dient goed te keuren

2012

03-07

State Gazette act Capital & shares

Statutes amendment2 facts ▸

General meeting, 11 juni 2012
Statutes amendment

2011

20-04

State Gazette act Restructuring

Merger · Name change · Power of attorney5 facts ▸

General meeting, april 2011
Merger, met fusie door overneming gelijkgestelde verrichting
Name change, ACA PHARMA
Power of attorney, Ann DE SMEDT
Power of attorney, Rony LEBOTTE

24-02

State Gazette act Restructuring

Merger1 fact ▸

Merger, absorption

2010

21-12

State Gazette act Capital & shares

Change of control2 facts ▸

General meeting, 06/12/2010
Change of control, true

22-09

State Gazette act Appointment: PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)

Permanent representative: Peter Opsomer · Power of attorney4 facts ▸

General meeting, 11/05/2010
Auditor appointment, PricewaterhouseCoopers Bedrijfsrevisoren (statutory auditor)
Permanent representative, Peter Opsomer
Power of attorney, BV BVBA Peter Opsomer

02-03

State Gazette act Statutes amendment

Capital · Language change3 facts ▸

General meeting, 12/02/2010
Capital, €52.892.207
Language change, van het Franse naar het Nederlandse taalgebied

12-01

State Gazette act Resignations & appointments · End & cessation

Statutes amendment3 facts ▸

General meeting, 22 décembre 2009
Corporate decision, Annulation de la décision de modifier la dénomination de la société prise le 14 octobre 2009
Statutes amendment

2009

09-11

State Gazette act Registered office · Resignations & appointments

Name change · Registered-office move · Statutes amendment5 facts ▸

General meeting, 14 octobre 2009
Name change, ACA PHARMA
Registered-office move, 8790 Waregem, Textielstraat 24
Statutes amendment
Statutes amendment

2007

01-10

State Gazette act Assemblee Generale

General meeting1 fact ▸

General meeting, 20/09/2007

22-06

State Gazette act Appointment: SCCRL PricewaterhouseCoupers (réviseurs d'entreprises)

2 facts ▸

General meeting, 30 mars 2007
Auditor appointment, SCCRL PricewaterhouseCoupers (réviseurs d'entreprises)

2006

02-01

State Gazette act Restructuring

Merger · Dissolution · Power of attorney5 facts ▸

Merger, 07/12/2005
Dissolution, 07-12-2005
Power of attorney, Rony LEBOTTE
Reference date, 30/06/2005
Shareholding, 100%

2005

10-10

State Gazette act Restructuring · Miscellaneous

Merger1 fact ▸

Merger, 26/09/2005

24-01

State Gazette act Capital & shares · Statutes amendment · Resignations & appointments

5 facts ▸

General meeting, 29/12/2004
Statutes amendment
Statutes amendment
Statutes amendment
Statutes amendment

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.An act published in both Dutch and French appears here once.

55 of 55 acts read

Directors · office · real estate

Directors

3 directors, 1 in day-to-day management, no change since 2026

Board 3

Céline Caveye

Director · since 01-07-2016

Current

Padilla Rafael

Director · since 04-12-2017

Current

De Jong Cormelia Neeltje

Director · since 10-05-2022

Current

2 not recently confirmed

Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.

JAN PEETERS

Director · since 14-05-2013 · Public limited company · perm. rep.: Jan Peeters

Not recently confirmed

Cornelia de Jong

Director · since 17-10-2016

Not recently confirmed

Day-to-day management 1

Peter De Sutter

Day-to-day manager · since 01-04-2021

Current

2 not recently confirmed

Still in office according to the acts, but no act of the last six years confirms the mandate. It has often ended since, in an act we have not read.

JAN PEETERS

Managing director · since 14-05-2013 · Public limited company · perm. rep.: Jan Peeters

Not recently confirmed

Cornelia de Jong

Managing director · since 04-12-2017

Not recently confirmed

Permanent representatives 1

Jan Peeters

Permanent representative · since 14-05-2013 · for JAN PEETERS

Not recently confirmed

Statutory auditor 1

Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises

Statutory auditor · since 16-10-2019

Current

Derived from published Gazette acts. The CBE keeps the official list of function holders; we do not read it, so the two can differ. See the function holders in the CBE →

Location & real-estate footprint

Registered office, Nazareth-De Pinte · 1 establishment unit since 1992

seat establishment The establishment unit on the map

Ground area

1.6 ha

Building footprint

7,285 m²

Volume, LiDAR

70,207 m³

Parcel 44048A0094/00L000, Flanders · tallest building 21.6 m, ±2 floors. Linked by address, not a title deed.

5 companies at this address See who is registered here

1 establishment unit

Infinity Pharma NV

Venecoweg 20A, 9810 Nazareth-De PinteAir transport

since 19922.013.193.230

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
44048A0094/00L000	Flanders	1.6 ha	1 · 7,284 m²	21.6 m · 2 fl.

Linked by address, not proof of ownership

Good to know

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Mandate history

23 people since 2007, 7 in office

All 23 In office 7 Ended 16

Board
Day-to-day management
Statutory auditor
not recently confirmed
began earlier

Mandates per person, with start and end dates
Name	Functions and periods
Céline Caveye	Director, from 01-07-2016 to date
Padilla Rafael	Director, from 04-12-2017 to date
De Jong Cormelia Neeltje	Director, already before 10-05-2022 to date
Peter De Sutter	Day-to-day manager, from 01-04-2021 to date
Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises	Statutory auditor, from 16-10-2019 to date
JAN PEETERS	Director, already before 14-05-2013 not ended, last confirmed 06-02-2014 Managing director, from 14-05-2013 not ended, last confirmed 06-02-2014
Cornelia de Jong	Director, from 17-10-2016 not ended, last confirmed 20-12-2016 Managing director, from 04-12-2017 not ended, last confirmed 08-02-2018
Johan Verlinden	Director, from 01-07-2016 to 07-07-2026
Bart Ameije	Day-to-day manager, from 01-09-2019 to 01-04-2021
Hernando Acosta	Day-to-day manager, from 01-10-2020 to 01-03-2021
PricewaterhouseCoopers Reviseurs d'Entreprises	Statutory auditor, from 22-09-2010 to 16-10-2019
Jumoo bvba	Day-to-day manager, from 01-09-2017 to 25-03-2019
Johannes Stols	Director, from 12-12-2015 to 04-12-2017 Managing director, from 12-12-2015 ended, last mentioned 23-03-2016
Kalman Petro	Day-to-day manager, from 01-04-2017 to 01-09-2017
Davy De Vlieger	Day-to-day manager, from 01-04-2017 to 01-06-2017
BOUVRY Christophe	Day-to-day manager, from 17-10-2016 to 01-04-2017
Procuram bvba	Day-to-day manager, from 01-01-2014 to 01-04-2017
Tim Delameilleure	Day-to-day manager, from 17-10-2016 to 01-04-2017
Jan Peeters NV	Director, until 17-10-2016
Rony Lebotte	Day-to-day manager, from 01-01-2014 to 17-10-2016
Gerardus van Jeveren	Director, from 14-05-2013 to 12-12-2015 Director and managing director, until 12-12-2015
BVBA ROMANI MANAGEMENT	Day-to-day manager, from 01-01-2014 to 25-04-2014
SCCRL PricewaterhouseCoupers	Réviseurs d'entreprises, from 22-06-2007 to 22-09-2010

Show all 23 people Show the first 12See the board, name and seat on a given date →

Articles of association

Purpose

De vennootschap heeft tot voorwerp: De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de verkoop…

Full purpose

De vennootschap heeft tot voorwerp: De studie, het onderzoek, het ontwerp, de analyse, de beschouwing, de farmacodynamie, de productie, de vervaardiging, de promotie, de verkoop, de handel, de vertegenwoordiging, de makelarij, de opslag van allerhande chemische producten en andere, al dan niet therapeutisch, farmaceutisch, farmacologisch, de handel, de import van allerhande producten, gereedschappen, apparaten en extracten, parfums, schoonheidsproducten, aromatherapie, allerhande voedingsmiddelen, therapeutische middelen voor mensen, dieren en planten. Zij mag alle samenhangende handels-en nijverheidsverrichtingen stellen die kunnen bijdragen tot de ontwikkeling van haar onderneming en in het algemeen alle roerende, onroerende en financiële verrichtingen stellen en onder om het even welke vorm deelnemen aan alle ondernemingen waarvan het voorwerp aanverwant is aan of samenhangend is met het hare..

according to the deed of 03-05-2023

Board rule

Toevoeging na bestaande tekst, 15

according to the deed of 07-07-2026

Structure & network

Owners and holdings

3 holdings

Owners 0

The accounts to 31-12-2025 list no shareholders, and no other source names one.

Holdings 3

FAGRON BELGIUMsubsidiary

Sourceown accounts 2025 accounts FAGRON BELGIUM 2025
Equity €25,600Result -€1.9m

100%
FAGRON COMPOUNDING SERVICESsubsidiary

Sourceown accounts 2025 accounts FAGRON COMPOUNDING SERVICES 2024
Equity €456,496Result €263,263

100%
ABC DENTAL AND PHARMACEUTICAL CONSULTANCY

Sourceown accounts 2025 accounts ABC DENTAL AND PHARMACEUTICAL CONSULTANCY 2025
Equity €34.9mResult €1.3m

0.01%

Stated earlier (1)

An older source named these holdings; newer accounts no longer list them.

VERRERIE VERVIÉTOISE

Sourceact 02-01-2006

100%

According to the 2025 annual accounts of INFINITY PHARMA and those of the other companies, the acts in the Belgian Gazette and the LEI register. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not fill in these statements, or need not, is missing.

Connections & network

8 connected companies

Depth

Shared directors

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, scroll to zoom.

Linked via shared directors

Belgian Association of Consumer Healthcare Industry

Shared director

→

FEDERATION DE L'INDUSTRIE ALIMENTAIRE - FEDERATIE VOEDINGSINDUSTRIE

Shared director

→

GREEN MONKEY

Shared director

→

isomasters

Shared director

→

Show 4 more companies with a shared director

KINGSPAN

Shared director

→

Make-A-Wish Belgium - Vlaanderen

Shared director

→

FAGRON CAPITAL

Shared corporate director

→

SOFT 33

Shared corporate director

→

Acquisitions and mergers

8 transactions

Took over:PHARMA-PACK

BE 0426.468.517State Gazette act of 03-08-2023 (2 acts) · effective 21-06-2023

Took over:INFINITY PHARMA

BE 0883.273.090operation treated as a merger by absorption · State Gazette act of 26-07-2021 (2 acts)

Took over:ARSEUS BELGIË

BE 0434.900.191State Gazette act of 13-08-2020 (2 acts)

Took over:ACCESSOIRES ET PRODUITS PHARMACEUTIQUES EN GROS

BE 0456.622.154State Gazette act of 27-12-2018 (2 acts)

Took over:BELGOPHAR

BE 0860.437.213State Gazette act of 27-12-2018 (2 acts)

Took over:EUPHACO

BE 0542.502.588merger by absorption · State Gazette act of 10-07-2018 (2 acts)

Took over:A.C.A. - PHARMA

BE 0416.121.783operation treated as a merger by absorption · State Gazette act of 20-04-2011

Took over:VERRERIE VERVIÉTOISE

BE 0414.436.656merger by absorption · State Gazette act of 02-01-2006 · effective 07-12-2005

Capital and shareholders

Capital over the years

02-01-2026 Capital increase of 4,000,000 EUR · to 13,300,000 EUR · in cash
23-01-2025 Capital increase of 15,009,359.36 EUR · to 16,668,329.98 EUR · in cash
23-01-2025 Capital reduction of 7,368,329.98 EUR · to 9,300,000 EUR · “aanzuivering van verliezen”
26-07-2021 Capital stated in the act · 1,658,970.62 EUR · 1,366,595 shares
10-07-2018 Capital increase of 99,873.22 EUR · to 799,872.46 EUR · 170,635 new shares
10-07-2018 Capital increase of 859,098.16 EUR · to 1,658,970.62 EUR · no new shares
30-11-2017 Capital reduction of 186,169,363.76 EUR · to 699,999.24 EUR · “uitkering in natura van een deel van de ... vordering”
05-05-2014 Capital increase of 133,977,156 EUR · to 186,869,363 EUR · 857,451 new shares · schuldvordering

Show 1 older capital entries

02-03-2010 Capital stated in the act · 52,892,207 EUR

Recognitions · licences · registrations

Food safety, FASFC

1 site

Nazareth-De Pinte2.013.193.230

1 permission

Groothandelaar LM>3 maand · since 23-06-2023

Similar companies · same sector, comparable size

CYTIVA BELGIUM

BE 0783.590.249

Hoegaarden · Eq €16,456,145

MEDISCH LABO SERVICE

BE 0429.447.902

Menen · Eq €16,664,435

GETINGE BELGIUM

BE 0416.342.905

Dilbeek · Eq €16,678,446

sandoz

BE 0457.517.227

Machelen (Brab.) · Eq €16,786,397

THERABEL IMMO

BE 0428.944.292

Vorst · Eq €15,592,636

Of 1,903 companies in sector 46460 we hold annual accounts for 1,126. 362 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector

Identification & contact

Identification

Legal formPublic limited company

Founded08-12-1976

Fiscal year end31-12

Legal name NL PHARMA-PACK

Activities, NACEBEL 2025

46460Wholesale of pharmaceutical and medical goods

E-invoicing

Reachable via Peppol

Peppol ID 0208:0416616681

Registered 01-10-2025

Scores and ratios are computed by Checked and are not a credit decision.